IL17A and myeloid sarcoma: The addition of IL-27 to CD4+ T cells from patients with MS downregulated the percentage of CD4+IL-17A+ and CD4+GM-CSF+ T cells, reduced the expression of IL-17A, but activated STAT3 signaling (169).